SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-000999
Filing Date
2024-01-04
Accepted
2024-01-04 08:11:19
Documents
14
Period of Report
2024-01-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea191114-8k_relmada.htm   iXBRL 8-K 28386
2 PRESS RELEASE ISSUED ON JANUARY 4, 2024 ea191114ex99-1_relmada.htm EX-99.1 15447
3 GRAPHIC ex99-1_001.jpg GRAPHIC 6374
  Complete submission text file 0001213900-24-000999.txt   231014

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rlmd-20240104.xsd EX-101.SCH 3012
5 XBRL LABEL FILE rlmd-20240104_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE rlmd-20240104_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT ea191114-8k_relmada_htm.xml XML 3331
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 24509812
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)